

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SHAO et al

Art Unit: 1642

Serial No. 09/817,199

Examiner: S. Rawlings

Filed: March 27, 2001

Atty. Docket: CL001187

For: ISOLATED HUMAN RAS-LIKE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING THESE
HUMAN RAS-LIKE PROTEINS, AND USES THEREOF

**Submission Of Third Substitute Sequence Listing
Under 37 CFR § 1.821(a)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), and in response to the Office Communication mailed June 18, 2003, applicants submit a Third Substitute Sequence Listing, including a paper copy of the Third Substitute Sequence Listing and a computer readable copy of the Third Substitute Sequence Listing.

Please replace the Second Substitute Sequence Listing submitted April 14, 2003 (as well as the Substitute Sequence Listing submitted July 17, 2002, and the Sequence Listing originally submitted March 27, 2001) with the Third Substitute Sequence Listing submitted herewith.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Third Substitute Sequence Listing and the computer readable copy of the Third Substitute Sequence Listing submitted herewith in the above application are identical and include no new matter.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

Date: July 18, 2003

By: 


Justin D. Karjala, Reg. 43,704

Celera Genomics
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3812 / Fax: 240-453-3084



RECEIVED
JUL 22 2003
TECH CENTER 1600/2000

Notice to Comply



Application No.

09/817,199

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)

SHAO ET AL.

Art Unit

1642

RECEIVED
JUL 22 2003
TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: There remains the disclosure of the amino acid sequence, "DTAGQ" at page 3, which is not properly identified by a sequence identification number. If necessary, Applicants are required to submit substitute copies of the sequence listing, as indicated below.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY